These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 38342243)

  • 1. Emerging strategies for nanomedicine in autoimmunity.
    Thatte AS; Billingsley MM; Weissman D; Melamed JR; Mitchell MJ
    Adv Drug Deliv Rev; 2024 Apr; 207():115194. PubMed ID: 38342243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tackling autoimmunity with nanomedicines.
    Feng X; Liu J; Xu W; Li G; Ding J
    Nanomedicine (Lond); 2020 Jul; 15(16):1585-1597. PubMed ID: 32669025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic applications of nanomedicine in autoimmune diseases: from immunosuppression to tolerance induction.
    Gharagozloo M; Majewski S; Foldvari M
    Nanomedicine; 2015 May; 11(4):1003-18. PubMed ID: 25596076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunomodulatory and immunoregulatory nanomedicines for autoimmunity.
    Montaño J; Garnica J; Santamaria P
    Semin Immunol; 2021 Aug; 56():101535. PubMed ID: 34969600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide-MHC-Based Nanomedicines for the Treatment of Autoimmunity: Engineering, Mechanisms, and Diseases.
    Serra P; Santamaria P
    Front Immunol; 2020; 11():621774. PubMed ID: 33574822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine in autoimmunity.
    Clemente-Casares X; Santamaria P
    Immunol Lett; 2014; 158(1-2):167-74. PubMed ID: 24406504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Delivering safer immunotherapies for cancer.
    Milling L; Zhang Y; Irvine DJ
    Adv Drug Deliv Rev; 2017 May; 114():79-101. PubMed ID: 28545888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of nanomedicines for the treatment of autoimmune disease: From vehicles for drug delivery to inducers of bystander immunoregulation.
    Yang Y; Santamaria P
    Adv Drug Deliv Rev; 2021 Sep; 176():113898. PubMed ID: 34314782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanomedicine in cancer therapy.
    Fan D; Cao Y; Cao M; Wang Y; Cao Y; Gong T
    Signal Transduct Target Ther; 2023 Aug; 8(1):293. PubMed ID: 37544972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines for cancer therapy: current status, challenges and future prospects.
    Bor G; Mat Azmi ID; Yaghmur A
    Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating human autoimmunity: current practice and future prospects.
    Rosenblum MD; Gratz IK; Paw JS; Abbas AK
    Sci Transl Med; 2012 Mar; 4(125):125sr1. PubMed ID: 22422994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoparticle-neutrophils interactions for autoimmune regulation.
    Kupor D; Felder ML; Kodikalla S; Chu X; Eniola-Adefeso O
    Adv Drug Deliv Rev; 2024 Jun; 209():115316. PubMed ID: 38663550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Smart Nanosystems for Overcoming Multiple Biological Barriers in Cancer Nanomedicines Transport: Design Principles, Progress, and Challenges.
    Lin G; Zhou J; Cheng H; Liu G
    Small; 2023 Jul; 19(28):e2207973. PubMed ID: 36971279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-Targeted Nanomedicine for Immunotherapy.
    Cabral H; Kinoh H; Kataoka K
    Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyprodrug Nanomedicines: An Emerging Paradigm for Cancer Therapy.
    Yang K; Yang Z; Yu G; Nie Z; Wang R; Chen X
    Adv Mater; 2022 Feb; 34(6):e2107434. PubMed ID: 34693571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-Acidity-Cleavable Maleic Acid Amide (TACMAA): A Powerful Tool for Designing Smart Nanoparticles To Overcome Delivery Barriers in Cancer Nanomedicine.
    Du JZ; Li HJ; Wang J
    Acc Chem Res; 2018 Nov; 51(11):2848-2856. PubMed ID: 30346728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases.
    Prosperi D; Colombo M; Zanoni I; Granucci F
    Semin Immunol; 2017 Dec; 34():61-67. PubMed ID: 28855088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An All-in-One Nanomedicine Consisting of CRISPR-Cas9 and an Autoantigen Peptide for Restoring Specific Immune Tolerance.
    Luo YL; Liang LF; Gan YJ; Liu J; Zhang Y; Fan YN; Zhao G; Czarna A; Lu ZD; Du XJ; Shen S; Xu CF; Lian ZX; Wang J
    ACS Appl Mater Interfaces; 2020 Oct; 12(43):48259-48271. PubMed ID: 33070614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-Generation Polymeric Nanomedicines for Oncology: Perspectives and Future Directions.
    Fletcher NL; Kempe K; Thurecht KJ
    Macromol Rapid Commun; 2020 Sep; 41(18):e2000319. PubMed ID: 32767396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.